

Enzon Incorporated

[View the current Enzon Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/3851-Enzon+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/3851-Enzon+Incorporated.html>)

Contact Details:

20 Kingsbridge Road

Piscataway

NJ

08854

United States of America

Tel: 732 980 4500

Fax: 732 980 5911

Email:

Enzon Incorporated is a biopharmaceutical company that develops, manufactures and markets enhanced therapeutics for life-threatening diseases through the application of its two proprietary technologies: (i) polyethylene glycol ("PEG") Modification or the PEG Process and (ii) single-chain antigen-binding ("SCA(R)") proteins. Enzon is focusing its internal research activities on applying its proprietary technologies to compounds of known therapeutic efficacy in order to enhance the performance of these compounds. Enzon is commercializing its proprietary technologies by developing products internally and in cooperation with strategic partners. To date, Enzon and its partners have successfully commercialized two products, ONCASPAR(R) and ADAGEN(R).

Recent Publications by Enzon Incorporated:



- [Novel prodrugs of SN38 using multiarm poly\(ethylene glycol\) linkers.](#)
CPT-11, also known as irinotecan, is a prodrug that is approved for the... 29th July, 2008
Enzon Pharmaceuticals, Inc., 20 Kingsbridge Road, Piscataway, New Jersey- Bioconjug Chem. 2008 Apr;19(4):849-59. Epub 2008 Mar 28. ([DOI Direct Link](#))
- [Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.](#)
PURPOSE: Clinical development of SN38, the active metabolite of... 21st May, 2008
Enzon Pharmaceuticals, Inc., Piscataway, New Jersey 08854, USA.- Clin Cancer Res. 2008 Mar 15;14(6):1888-96. ([DOI Direct Link](#))
- [Releasable PEGylation of proteins with customized linkers.](#)
Releasable PEGylation employs customized linkers that reversibly tether a... 6th May, 2008
Enzon Pharmaceuticals, Inc., 20 Kingsbridge Road, Piscataway, New Jersey- Adv Drug Deliv Rev. 2008 Jan 3;60(1):29-49. Epub 2007 Aug 16. ([DOI Direct Link](#))

- [Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.](#)
*Recombinant immunotoxins exhibit targeting and cytotoxic functions needed...*30th August, 2007
Enzon Pharmaceuticals, Incorporated, 20 Kingsbridge Road, Piscataway, New- Bioconjug Chem. 2007 May-Jun;18(3):773-84. Epub 2007 Mar 9. ([DOI Direct Link](#))
- [Antibody engineering and modification technologies.](#)
*Antibody engineering has become a well-developed discipline, encompassing...*27th July, 2007
Enzon Pharmaceuticals, Piscataway, NJ 08854-3969, USA.- Biomol Eng. 2007 Jun;24(2):201-15. Epub 2007 Mar 31. ([DOI Direct Link](#))
- [Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy.](#)
*In order to overcome the problems of enzymatic degradation and short...*11th July, 2007
Enzon Pharmaceuticals, 20 Kingsbridge Road, Piscataway, NJ 08820, United- J Control Release. 2007 Jun 4;119(2):143-52. Epub 2006 Dec 29. ([DOI Direct Link](#))
- [Comparative immunotoxicity evaluation of amphotericin B and ABELCET, an amphotericin B lipid complex \(ABLC\).](#)
*ABELCET, an amphotericin B lipid complex formulation (ABLC) and an...*8th February, 2007
Enzon Pharmaceuticals, Inc., Piscataway, New Jersey 08854, USA.- Int J Toxicol. 2006 Nov-Dec;25(6):487-92. ([DOI Direct Link](#))
- [Antitumor activity of poly\(ethylene glycol\)-camptothecin conjugate: the inhibition of tumor growth in vivo.](#)
*Antitumor effect of poly(ethylene glycol)-camptothecin conjugate (PEG-CPT)...*20th January, 2007
Enzon Pharmaceuticals, Inc., Piscataway, NJ 08854, USA.- J Control Release. 2005 Dec 10;110(1):90-102. Epub 2005 Nov 4. ([DOI Direct Link](#))
- [Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritis.](#)
*Arginine is an important metabolite in the normal function of several...*16th January, 2007
Enzon Pharmaceuticals, 20 Kingsbridge Road, Piscataway, New Jersey- Bioconjug Chem. 2006 Nov-Dec;17(6):1447-59. ([DOI Direct Link](#))
- [Safety evaluation of ABELCET, an amphotericin B lipid complex \(ABLC\): toxicity studies in rats.](#)
*ABELCET (ABLC) is a widely used amphotericin B lipid complex formulation...*19th August, 2006
Enzon Pharmaceuticals, Inc., Piscataway, New Jersey, USA.- Int J Toxicol. 2006 Jul-Aug;25(4):285-94. ([DOI Direct Link](#))
- [Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.](#)
*Recombinant interferon-beta-1b (IFN-beta-1b) is used clinically in the...*25th July, 2006
Enzon Pharmaceuticals, 20 Kingsbridge Road, Piscataway, New Jersey- Bioconjug Chem. 2006 May-Jun;17(3):618-30. ([DOI Direct Link](#))
- [Linear and branched bicin linkers for releasable PEGylation of macromolecules: controlled release in vivo and in vitro from mono- and multi-PEGylated proteins.](#)
*The utility of PEGylation for improving therapeutic protein pharmacology...*13th July, 2006
Enzon Pharmaceuticals, Inc., 20 Kingsbridge Road, Piscataway, New Jersey- Bioconjug Chem. 2006 Mar-Apr;17(2):341-51. ([DOI Direct Link](#))
- [An unexpected amide bond cleavage: poly \(ethylene glycol\) transport forms of vancomycin. 2.](#)
*PEG-amide vancomycin derivatives (V(3) position) have been synthesized and...*7th January, 2006
Enzon Pharmaceuticals, Inc., 20 Kingsbridge Road, Piscataway, NJ 08854,- Eur J Med Chem. 2005 Aug;40(8):798-804. Epub 2005 Apr 22. ([DOI Direct Link](#))
- [A new platform for oligonucleotide delivery utilizing the PEG prodrug approach.](#)
*The oligonucleotide (oligo, ODN), Genasense (GS), an ODN currently waiting...*13th December, 2005
Enzon Pharmaceuticals Inc., 20 Kingsbridge Road, Piscataway, New Jersey- Bioconjug Chem. 2005 Jul-Aug;16(4):758-66. ([DOI Direct Link](#))

- [Enzon Pharmaceuticals exploring alternatives](#)
Home News Tribune: Aug 23 2008 8:18PM Matching: enzon
- [Enzon may sell Indy plant alongside specialty pharma](#)
Outsourcing Pharma: Aug 20 2008 3:15AM Matching: enzon
- [Lance Armstrong Foundation receives the CEO Cancer Gold Standard](#)
Live Strong: Aug 20 2008 7:34AM Matching: enzon
- [The Lance Armstrong Foundation Receives CEO Cancer Gold Standard™ Accreditation](#)
FinanzNachrichten.de: Aug 19 2008 8:37AM Matching: enzon
- [The Lance Armstrong Foundation Receives CEO Cancer Gold Standard™ Accreditation](#)
Business Wire: Aug 19 2008 8:13AM Matching: enzon
- [\[external\] When Breaking Up Isn't Hard to Do](#)
Yahoo!: Aug 18 2008 7:58PM Matching: enzon
- [Enzon Pharma Risks Balanced](#)
Yahoo!: Aug 18 2008 2:03PM Matching: enzon
- [Enzon Pharmaceuticals Announces Intention to Explore Strategic Alternatives for Specialty Pharmaceuticals Busi](#)
DiGiTAL50: Aug 16 2008 12:54AM Matching: enzon
- [Enzon Pharmaceuticals Announces Intention To Explore Strategic Alternatives For Specialty Pharmaceutical](#)
Pharmaceutical Online: Aug 14 2008 12:04PM Matching: enzon
- [Company and People Notes: Genentech Rejects Roche's Bid, TorreyPines CEO Retires, More](#)
Pharmaceutical Technology: Aug 14 2008 2:12PM Matching: enzon
- [Enzon Pharma may sell off entire specialty pharma business](#)
PharmaBiz: Aug 13 2008 5:32AM Matching: enzon
- [Enzon to explore possible sale of unit](#)
Clinical Lab Products: Aug 13 2008 1:21AM Matching: enzon
- [Enzon Continues to Pursue Plan to Spin-off Biotechnology Business](#)
Citybizlist: Aug 12 2008 2:15AM Matching: enzon
- [Enzon Pharmaceuticals Announces Intention To Explore Strategic Alternatives For Specialty Pharmaceuticals Busi](#)
Pharmaceutical Online: Aug 12 2008 5:04AM Matching: enzon
- [Enzon considering selling specialty business](#)
Pharma Times: Aug 12 2008 10:49AM Matching: enzon

Enzon Incorporated Patents:



- 6011042- [Acyl polymeric derivatives of aromatic hydroxyl-containing compounds](#)
- 6194580- [High yield method for stereoselective acylation of tertiary alcohols](#)
- 6214330- [Coumarin and related aromatic-based polymeric prodrugs](#)

- 6251382- [Biodegradable high molecular weight polymeric linkers and their conjugates](#)
- 6303569- [Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents](#)
- 6323322- [Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof](#)
- 6333396- [Method for targeted delivery of nucleic acids](#)
- 6376470- [Polymer conjugates of ara-C and ara-C derivatives](#)
- 6395266- [Terminally-branched polymeric linkers and polymeric conjugates containing the same](#)
- 6515110- [Multivalent antigen-binding proteins](#)
- 6566506- [Non-antigenic branched polymer conjugates](#)
- 6180095- [Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents](#)
- 6177087- [Non-antigenic amine derived polymers and polymer conjugates](#)
- 6153655- [Terminally-branched polymeric linkers and polymeric conjugates containing the same](#)
- 6013283- [Alkyl or olefinic endcapped polyalkylene oxide solubilizer](#)
- 6025165- [Methods for producing multivalent antigen-binding proteins](#)
- 6027725- [Multivalent antigen-binding proteins](#)
- 6042822- [Interferon polymer conjugates](#)
- 6103889- [Nucleic acid molecules encoding single-chain antigen-binding proteins](#)
- 6111107- [High yield method for stereoselective acylation of tertiary alcohols](#)
- 6113906- [Water-soluble non-antigenic polymer linkable to biologically active material](#)
- 6121424- [Multivalent antigen-binding proteins](#)
- 6127355- [High molecular weight polymer-based prodrugs](#)
- 6132713- [Arginine deiminase derived from mycoplasma arthritidis and polymer conjugates containing the same](#)
- 6608076- [Camptothecin derivatives and polymeric conjugates thereof](#)
- 6624142- [Trimethyl lock based tetrapartate prodrugs](#)
- 6936597- [Prodrugs of anticancer agents employing substituted aromatic acids](#)
- 7033583- [Polymeric thiol-linked prodrugs](#)
- 7087229- [Releasable polymeric conjugates based on aliphatic biodegradable linkers](#)
- 7122189- [Releasable polymeric conjugates based on aliphatic biodegradable linkers](#)
- 7150872- [Polyalkylene oxide-modified single chain polypeptides](#)
- 7262164- [Polymeric thiol-linked prodrugs employing benzyl elimination systems](#)
- 7273845- [Polymeric prodrugs of vancomycin](#)
- 7301003- [Method of preparing polymers having terminal amine groups](#)
- 7332164- [Heterobifunctional polymeric bioconjugates](#)
- 7365127- [Process for the preparation of polymer conjugates](#)
- 6872393- [Polyalkylene oxide-modified single chain polypeptides](#)
- 6824782- [Polyalkylene oxide-modified single chain polypeptides](#)
- 6824766- [Biodegradable high molecular weight polymeric linkers and their conjugates](#)
- 6638499- [Terminally-branched polymeric linkers and polymeric conjugates containing the same](#)
- 6649778- [Methods of preparing amino acid taxane derivatives and polymer conjugates containing the same](#)
- 6689762- [Composition and methods for treatment of HIV infection](#)
- 6692942- [Single-chain polypeptides for targeted delivery of nucleic acids](#)
- 6720306- [Tetrapartate prodrugs](#)
- 6743896- [Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof](#)
- 6743908- [Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof](#)
- 6756037- [Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups](#)
- 6764853- [Method for targeted delivery of nucleic acids](#)
- 6777387- [Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same](#)
- 7393953- [Polymeric acyl derivatives of indoles](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's relate service indepth.

The annual cost is \$495.00 for established organizations and \$295.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

